The pan-PI3K inhibitor buparlisib (BKM120) is, however, well tolerated in mice, and in vivo preclinical studies in a variety of cancer types have reported anti-tumor efficacy associated with reduced AKT activity in response to buparlisib treatment, including prostate cancer models [21,159,160,161,162]. Here, PIK3CD is linked to neoplasm.